Gilead Sciences Signs HIV Generics Deal With Indian Pharmas

Gilead Sciences Inc. has signed an agreement with three Indian companies to promote access to generic versions of its HIV drug.

AsianScientist (Aug. 6, 2012) – Gilead Sciences Inc., has signed an agreement with three Indian companies – Strides Arcolabs Ltd., Ranbaxy Laboratories Ltd., and Mylan Laboratories Ltd. – to collaborate on promoting access to high-quality, low-cost generic versions of its HIV medicine emtricitabine (FTC) in developing countries.

The California-based Gilead Sciences is the world’s biggest manufacturer of HIV drugs.

Under the new agreements, Gilead will provide a technology transfer for the manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce overall manufacturing costs.

The deal includes single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

World Health Organization guidelines recommend emtricitabine, as well as tenofovir disoproxil fumarate (TDF), as preferred components of first- and second-line HIV therapy.

Cost, however, is a barrier to broadening access to regimens that include emtricitabine when compared to other regimens, including widely used lamivudine (3TC)-based regimens. The new agreements are designed to help Gilead’s Indian generic partners establish sustainable price parity to these alternative regimens.

“Ongoing collaboration (with Indian companies) will be critical for furthering access to affordable, high-quality, first-line HIV treatment for developing countries,” said John C. Martin, Chairman and Chief Executive Officer of Gilead.

“More than 2.7 million patients living with HIV in developing countries are currently receiving a TDF-containing regimen, a medicine innovated by Gilead and subsequently licensed to Indian generic partners to increase global access to effective treatment.” he added.

Emtricitabine is marketed by Gilead under the brand name Emtriva, and a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate is made available under the brand name Truvada, recently approved by U.S. Food and Drug Administration for HIV prevention therapy.

Emtricitabine is also an essential component of the Quad, an investigational treatment that combines four Gilead medicines in a once-daily, single tablet regimen for the treatment of HIV.


Source: Gilead Sciences, Inc.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Anis Rehman studied medicine at Dow Medical College, Pakistan and received research and clinical training at the Johns Hopkins University and University of Massachusetts, USA. He is the Founder and Associate Chief Editor at the Journal of Pakistan Medical Students (JPMS) and the co-founder and ex-Senior Vice President of the Pakistan Medical Students’ Research Society (PMSRS). Anis represents Pakistan at Healthcare Information for All (HIFA) - UK, works against child abuse, and volunteers for flood relief activities and related causes. He enjoys photography, traveling, food, web-designing, writing, and socializing.

Related Stories from Asian Scientist